[go: up one dir, main page]

FI964113A0 - Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö - Google Patents

Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö

Info

Publication number
FI964113A0
FI964113A0 FI964113A FI964113A FI964113A0 FI 964113 A0 FI964113 A0 FI 964113A0 FI 964113 A FI964113 A FI 964113A FI 964113 A FI964113 A FI 964113A FI 964113 A0 FI964113 A0 FI 964113A0
Authority
FI
Finland
Prior art keywords
treatment
medical composition
tardive dyskinesia
tardive
dyskinesia
Prior art date
Application number
FI964113A
Other languages
English (en)
Swedish (sv)
Other versions
FI964113A (fi
Inventor
Hajime Sasaki
Yohko Maeda
Kenji Hashimoto
Toshiya Inada
Yoshie Kitao
Original Assignee
Iyo Masaomi
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iyo Masaomi, Meiji Seika Kaisha filed Critical Iyo Masaomi
Publication of FI964113A publication Critical patent/FI964113A/fi
Publication of FI964113A0 publication Critical patent/FI964113A0/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
FI964113A 1994-04-15 1996-10-14 Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö FI964113A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7714694 1994-04-15
PCT/JP1995/000736 WO1995028177A1 (fr) 1994-04-15 1995-04-14 Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition

Publications (2)

Publication Number Publication Date
FI964113A FI964113A (fi) 1996-10-14
FI964113A0 true FI964113A0 (fi) 1996-10-14

Family

ID=13625663

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964113A FI964113A0 (fi) 1994-04-15 1996-10-14 Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö

Country Status (8)

Country Link
US (1) US5712282A (fi)
EP (1) EP0755685A4 (fi)
JP (1) JP3598116B2 (fi)
AU (1) AU2224195A (fi)
CA (1) CA2187086A1 (fi)
FI (1) FI964113A0 (fi)
NO (1) NO964330L (fi)
WO (1) WO1995028177A1 (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
AU775102B2 (en) * 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology
JP2004532809A (ja) * 2000-11-02 2004-10-28 リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク ホスホジエステラーゼ4型を阻害することによって、神経系の再生および修復を刺激するための方法
IL149106A0 (en) * 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
IL162850A0 (en) * 2002-01-04 2005-11-20 Ford Henry Health System Nitric oxide donors for treatment of disease and injury
JPWO2004002484A1 (ja) * 2002-06-26 2005-10-27 協和醗酵工業株式会社 ホスホジエステラーゼ阻害剤
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59148748A (ja) * 1983-02-10 1984-08-25 Takeda Chem Ind Ltd ノナペプチド
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬

Also Published As

Publication number Publication date
WO1995028177A1 (fr) 1995-10-26
EP0755685A1 (en) 1997-01-29
CA2187086A1 (en) 1995-10-26
US5712282A (en) 1998-01-27
JP3598116B2 (ja) 2004-12-08
NO964330D0 (no) 1996-10-11
AU2224195A (en) 1995-11-10
FI964113A (fi) 1996-10-14
NO964330L (no) 1996-10-11
EP0755685A4 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
FI971969A (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
FI970918A0 (fi) Yhdisteet ja menetelmät syövän hoitamiseksi
FI952926A0 (fi) Menetelmät allergioiden hoitamiseksi tai ehkäisemiMenetelmät allergioiden hoitamiseksi tai ehkäisemiseksi seksi
FI953479A (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
FI955051A (fi) Heterosyklisiä yhdisteitä ja niiden valmistus ja käyttö
FI950119A (fi) Ulkoinen miehen katetri, sovitin ja menetelmiä sen käyttämiseksi ja valmistamiseksi
FI953180A (fi) Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset
FI942993A (fi) Organoaluminoksituote ja sen käyttö
FI971568A (fi) Menetelmä resistenttien kasvainten hoitamiseksi
FI103704B1 (fi) Mikrobinvastainen koostumus, sen valmistusmenetelmä ja sen käyttö
FI962370A (fi) Laite tissuen valmistamiseksi
FI960483A0 (fi) Muunnettava koostumus ja menetelmät sen käyttämiseksi
FI971750A0 (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
FI963866A0 (fi) Immuuniterapeuttinen aine ja sen käyttö
FI965204A (fi) Bromelaiinin lääkekäyttö
FI972235A0 (fi) Menetelmä triaryylietyleenijohdannaisten käyttämiseksi osteoporoosin hoidossa ja ehkäisyssä
PT928193E (pt) Utilizacao de 1-hidroxi-2-piridonas para o tratamento de infeccoes da pele
FI964113A0 (fi) Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
FI962976A0 (fi) Viherkaihin hoitoon tarkoitettuja koostumuksia, jotka sisältävät beta-salpaajaa
FI953087A (fi) Selluloosa-aineen käsittely ja siinä käytettävät koostumukset
FI963947A (fi) Täydellisesti liuennut luukudos ja menetelmä sen valmistamiseksi
FI973392A0 (fi) Fluorihiilinesteiden käyttö kiihdyttämään keuhko- ja muiden kudosten kasvua
FI952373A0 (fi) Lämmöllä kovetettavissa oleva päällystysaine ja sen käyttö
FR2736833B1 (fr) Composition super-absorbante et pansement contenant cette composition
FI971459A (fi) Antosyanidiinin ja sen johdannaisten käyttö retroviraalisten infektioiden hoitoon